UPCOMING WEBINAR

Field Based Monitoring:  Best Practices for Pharmaceutical Companies

February 19, 2016
12:00 pm -1:00 pm EST

VIDEO
Introducing the I GLASS Field Based Monitoring Tool
RECENT EVENTS
Dr. Wendy Heckelman was a featured speaker at the 16th Pharmaceutical Compliance Congress and Best Practices Forum in Washington, D.C.
on October 21, 2015 pharma congress

PUBLICATIONS 

Spring, 2015
Field Based Monitoring, Mitigating Risk, Maximizing Success

 

 

February, 2013

Mitigating Compliance Risks Across the Sales Execution Cycle

Rx for Compliance

September, 2013 

How to Create a Culture of Compliant Business Writing  


May, 2012 

Creating a Culture of Compliance with Lessons from NASA and the OIG

 

August, 2011 

 
February, 2011
 
Optimizing Sales Performance with Field Based Monitoring
 

 

Pharm Rep

March, 2011  

Inspect What You Expect: Field Based monitoring programs can help companies avoid problems before they start

Pharm Exec logo 

October, 2009 

The Changing Pharmaceutical Sales Landscape

Special Offering:
 The 5C's of Transition Leadership®

A program designed to build capabilities for successful change execution
 

WHITE PAPER
Click here to request our latest White Paper:

Change Management:  A Strategic Implementation Approach
The 5Cs of Transition Leadership White Paper
The New Compliance Landscape
for Opioid Promotion
 
The  opioid abuse epidemic in the United States has grown dramatically in recent years. The number of opioid prescriptions in the U.S. increased from 144 million in 2002 to more than 259 million in 2012 1 .  Each day, 44 people in the United States die from an overdose of prescription painkillers 2 .  The issue has resulted in one of the most serious public health concerns of our time.  Policy makers and activists are looking for ways to address and reverse this problem.  The best solutions are likely to come from the combined efforts of patients, prescribers, health plan payers, government officials, and the opioid manufacturers. The compliance teams of opioid manufacturers must make sure their company's promotional efforts address the abuse concerns and risks of the drugs.
 
What are opioids?

Opioids are commonly prescribed medications for the treatment of chronic, non-cancerous pain, such as back pain or osteoarthritis. According to the Center for Disease Control (CDC), the most common drugs involved in prescription overdose death include:
  • Hydrocodone (e.g., Vicodin)
  • Oxycodone (e.g., OxyContin)
  • Oxymorphone (e.g., Opana)
  • Methadone (especially when prescribed for pain)
Recent trends likely to impact the opioid compliance landscape

On February 4, 2016 the FDA announced that it will conduct a sweeping review of agency policies aimed at reversing the "opioid abuse epidemic."  As part of this review, the FDA will re-examine the risk-benefit paradigm and update REMS requirements for opioids, as well as developing a new framework for opioid review, approval, and monitoring.
 
The outcome of this heightened scrutiny is certain to present regulatory/compliance challenges, along with new expectations for opioid manufacturers.

On February 5, 2016 a California judge sentenced a physician to 30 years to life for the murder of 3 of her patients that died as a result of prescription drug overdoses.  This was a precedent-setting case that is sure to have an impact on opioid prescribing behavior by physicians. There will likely be additional compliance pressures on opioid manufacturers to modify their promotional activities and further reinforce risk-benefit information.

What can the compliance teams of opioid manufacturers do proactively to address abuse?

Pharmaceutical compliance colleagues are expected to mitigate risk and help keep their organization in safe harbor.  The opioid promotional efforts of pharma companies are likely to be further scrutinized.  As such, the compliance teams should:
  • Clarify the opioid risk-benefit profile with all customer-facing colleagues
  • Reiterate any opioid REMS requirements with sales and medical teams
  • Provide training to ensure selling messages are understood and properly communicated
  • Establish a field based monitoring process to observe and validate compliant opioid selling behaviors

Based on recent trends and issues, the compliance landscape for opioids will change.  Make sure your organization's compliance department is prepared to respond to the changes.

Please contact us for more information on Field Based Monitoring and assistance with implementing FBM in your organization.
Sincerely,
WLH banner - excellence through change